The Medical Letter on Drugs and Therapeutics: Difference between revisions
Tcsouthpaw (talk | contribs) ←Created page with 'Since 1959, ''The Medical Letter on Drugs and Therapeutics'' has provided independent, unbiased critical evaluations of new drugs and sometimes older drugs when imp...' |
m Copying from Category:Italian-language journals to Category:English-Italian multilingual journals Diffusing per WP:DIFFUSE using Cat-a-lot |
||
| (102 intermediate revisions by 33 users not shown) | |||
| Line 1: | Line 1: | ||
{{more citations needed|date=April 2016}} |
|||
Since 1959, ''The Medical Letter on Drugs and Therapeutics'' has provided independent, unbiased critical evaluations of new drugs and sometimes older drugs when important new information becomes available. Occasionally new non-drug treatments or diagnostic aids are reviewed. |
|||
{{Infobox journal |
|||
| cover = <!-- Commented out because image was deleted: [[image:tml on drugs w-website.gif|200px|center]] --> |
|||
| discipline = [[Pharmacology]] |
|||
| language = English, French, Italian |
|||
| abbreviation = Med. Lett. Drugs Ther. |
|||
| publisher = [[The Medical Letter, Inc.]] |
|||
| country = |
|||
| history = 1959-present |
|||
| frequency = Biweekly |
|||
| website = http://secure.medicalletter.org/medicalletter |
|||
| ISSN = 1523-2859 |
|||
| OCLC = 40606056 |
|||
| LCCN = 00211546 |
|||
| CODEN = MELEAP |
|||
}} |
|||
'''''The Medical Letter on Drugs and Therapeutics''''' (commonly referred to as ''The Medical Letter'') is a [[Peer review|peer-reviewed]] biweekly [[medical journal]] providing evaluations of [[pharmaceutical drug]]s. It is published in English, French, and Italian. The journal is abstracted and indexed in [[Index medicus]]/[[MEDLINE]]/[[PubMed]]. An offshoot, ''Treatment Guidelines from the Medical Letter'' ({{ISSN|1541-2792}}) was published from 2002 to 2014, when it was integrated into this journal. |
|||
== Editorial process == |
|||
''The Medical Letter'' is published biweekly (26 issues/year) by [[The Medical Letter, Inc.]], which also publishes ''[[Treatment Guidelines from the Medical Letter]]'', and is available in several language versions: English (US and Canadian-adapted), French (Canadian-adapted and European), Italian and Japanese. |
|||
Articles for ''The Medical Letter'' are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of [[clinical trial]]s. A preliminary draft is circulated to every member of the advisory board and 10-20 other investigators with relevant clinical or experimental experience with the article's topic. Drafts are also provided to the [[Food and Drug Administration]] and [[Centers for Disease Control and Prevention]] and to all first authors of articles cited in the text. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents. The final version of the paper includes comments from the reviewers and is checked and edited for accuracy and readability.<ref>{{cite web |url=http://medlet-best.securesites.com/downloads/Editorialchart.pdf |title=Flowchart of the editorial process |accessdate=2010-06-29 |publisher=[[The Medical Letter, Inc.]] |format=PDF}}</ref> |
|||
== Publisher == |
|||
The journal is published by The Medical Letter, Inc., a [[nonprofit organization]] founded in 1958 by [[Arthur Kallet]] and Harold Aaron.<ref>{{Cite journal |title=The Medical Letter - 50th Anniversary |url=https://secure.medicalletter.org/TML-article-1304d |journal=The Medical Letter on Drugs and Therapeutics |publication-date=2009 |volume=51 |issue=1304 |pages=5}}</ref> It is independent of the pharmaceutical industry, supported by subscriptions, accepts no advertising, and has had a strict policy in place that in order to retain its objectivity, no reprints will be sold to the pharmaceutical industry.{{citation needed|date=April 2016}} |
|||
== |
== References == |
||
{{Reflist}} |
|||
| ⚫ | |||
An expert consultant or one of the editors prepares the preliminary report using both published and available unpublished studies that are carefully examined, paying special attention to the results of controlled clinical trials. |
|||
* {{Official website|http://secure.medicalletter.org/medicalletter}} |
|||
{{DEFAULTSORT:Medical Letter on Drugs and Therapeutics}} |
|||
The preliminary draft is edited and sent to every member of the Advisory Board, to 10-20 other investigators who have clinical and experimental experience with the drug or type of drug or disease under review, to the [[FDA]] and [[CDC]], to the first authors of all the articles cited in the text, to appropriate representatives of the pharmaceutical companies making the drugs under review, and often to companies that make competitor drugs as well. |
|||
[[Category:Academic journals established in 1959]] |
|||
[[Category:Pharmacology journals]] |
|||
Many critical observations, suggestions and questions are received from the reviewers and are incorporated into the article during the revision process, and the article is checked and edited to make sure the final appraisal is not only accurate, but also easy to read. |
|||
[[Category:Multilingual journals]] |
|||
[[Category:English-language journals]] |
|||
[http://medlet-best.securesites.com/downloads/Editorialchart.pdf flowchart of the editorial process] |
|||
[[Category:French-language journals]] |
|||
[[Category:Italian-language journals]] |
|||
| ⚫ | |||
[[Category:English-Italian multilingual journals]] |
|||
[[Category:Biweekly journals]] |
|||
[http://www.medicalletter.org The Medical Letter website] |
|||
[http://medlet-best.securesites.com/html/ed.htm The Medical Letter Editorial and Advisory Board] |
|||
Latest revision as of 17:53, 6 January 2024
 | This article needs additional citations for verification. (April 2016) |
| Discipline | Pharmacology |
|---|---|
| Language | English, French, Italian |
| Publication details | |
| History | 1959-present |
| Publisher | |
| Frequency | Biweekly |
| Standard abbreviations | |
| ISO 4 | Med. Lett. Drugs Ther. |
| Indexing | |
| CODEN | MELEAP |
| ISSN | 1523-2859 |
| LCCN | 00211546 |
| OCLC no. | 40606056 |
| Links | |
The Medical Letter on Drugs and Therapeutics (commonly referred to as The Medical Letter) is a peer-reviewed biweekly medical journal providing evaluations of pharmaceutical drugs. It is published in English, French, and Italian. The journal is abstracted and indexed in Index medicus/MEDLINE/PubMed. An offshoot, Treatment Guidelines from the Medical Letter (ISSN 1541-2792) was published from 2002 to 2014, when it was integrated into this journal.
Editorial process
[edit]Articles for The Medical Letter are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trials. A preliminary draft is circulated to every member of the advisory board and 10-20 other investigators with relevant clinical or experimental experience with the article's topic. Drafts are also provided to the Food and Drug Administration and Centers for Disease Control and Prevention and to all first authors of articles cited in the text. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents. The final version of the paper includes comments from the reviewers and is checked and edited for accuracy and readability.[1]
Publisher
[edit]The journal is published by The Medical Letter, Inc., a nonprofit organization founded in 1958 by Arthur Kallet and Harold Aaron.[2] It is independent of the pharmaceutical industry, supported by subscriptions, accepts no advertising, and has had a strict policy in place that in order to retain its objectivity, no reprints will be sold to the pharmaceutical industry.[citation needed]
References
[edit]- ^ "Flowchart of the editorial process" (PDF). The Medical Letter, Inc. Retrieved 2010-06-29.
- ^ "The Medical Letter - 50th Anniversary". The Medical Letter on Drugs and Therapeutics. 51 (1304): 5. 2009.